New CAR T-Cell therapy targets tough blood cancers
NCT ID NCT07135466
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called SHB-04-CD22, which uses a patient's own immune cells (T-cells) engineered to find and attack cancer cells that have a protein called CD22. It is for children and adults (ages 1-80) with B-cell cancers that have come back or not responded to at least two prior treatments. The goal is to check if the therapy is safe and can shrink or eliminate the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sheba Medical Center
RECRUITINGRamat Gan, G, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?